A large international team reports that gemfibrozil, a cheap fibrate prescribed since the 1970s to lower blood fats, extends lifespan in yeast and worms and improves the health of aged mice. The surprise is the mechanism. The longevity effect has nothing to do with PPAR-alpha, the receptor that fibrates are famous for hitting. Instead, gemfibrozil binds and jams a cell-surface transporter called PEPT1 (Slc15a1) that normally ferries small peptides into cells. With the peptide door partly shut, cells absorb fewer amino acids, mTOR signalling drops, and the animals enter a state that looks biochemically like protein restriction or calorie restriction, without actually eating less. The authors frame gemfibrozil as a candidate “dietary restriction mimetic” already sitting on pharmacy shelves.
For decades the most reliable way to make an animal live longer has been to feed it less, or to feed it less protein. The problem is that almost no human sticks to that regimen. So the field keeps hunting for a pill that copies the internal signal of restriction while the person keeps eating normally. Rapamycin does it by blocking mTOR directly. Metformin and acarbose do it, roughly, through glucose handling. This paper nominates an unlikely new member of that club: gemfibrozil, a generic lipid drug most people have never heard of.
The researchers, led out of the National University of Singapore with the Buck Institute and Texas A&M, ran the drug through an unusually complete evolutionary gauntlet. In budding yeast it lengthened replicative lifespan by roughly a quarter. In roundworms it added about a tenth to median lifespan and kept the animals moving and stress-resistant later into life. Then they did the detective work to explain why.
The expected answer, PPAR-alpha, failed every test. Deleting the yeast versions of that target did not abolish the benefit, and two sister fibrate drugs did nothing at all. Using a protein-melting assay, the team caught gemfibrozil physically gripping a different protein entirely: PEPT1, the intestinal peptide transporter. Binding stiffened PEPT1 and choked off its ability to import di-peptides. Starve a cell of imported peptides and you starve it of amino acids, and amino acids are the fuel that switches on mTOR, the master growth engine that restriction is thought to quiet.
The pattern held across kingdoms. Yeast, worms, a human prostate cancer cell line, and slices of mouse intestine all imported fewer peptides and held lower internal amino acid levels after gemfibrozil. Genetically deleting the same transporters extended lifespan on their own, and once they were gone the drug added nothing, the signature of a drug and a gene acting on one shared pathway.
The headline mammalian result is health, not lifespan. Twenty-month-old female mice, already elderly, were put on gemfibrozil-laced chow. Over the following months their frailty scores climbed more slowly than untreated controls, with better grip strength, hearing, and coat-independent markers of vigour, and fewer deaths. This is preliminary and the mouse numbers are small, but the direction is consistent with everything upstream.
Insights
What the paper does reinforce, in a form you can act on today, is the underlying lever: lowering the flux of amino acids into your cells, especially from protein, quiets the growth pathway (mTOR) that appears to accelerate aging. The drug is essentially a chemical shortcut for what protein moderation does naturally.
How big is the effect? In the simplest, most translatable measurement, aged mice on the drug accumulated frailty 35 to 45 percent more slowly than untreated mice, and their death rate over the study window fell from 40 percent to about 22 to 27 percent. In relative terms that is roughly a one-third to nearly one-half reduction in the odds of dying during that window. Those are large numbers for a drug repurposing, but they come from small groups of mice and a short window, so treat the magnitude as a hopeful ceiling rather than a promise.
The defensible human lesson is that moderating protein intake, particularly in mid-life and for people under about 65 who still have muscle to spare, plausibly engages the same PEPT1 to mTOR axis this drug hijacks. The paper itself cautions that older, frailer people need adequate protein for muscle, so this is not a blanket “eat less protein” message.
Context and Source
- Open Access Paper: Gemfibrozil promotes longevity and health by restricting amino acid uptake through the Dipeptide transporter, PEPT1.
- Lead institution and country: National University of Singapore (Healthy Longevity Translational Research Programme, Yong Loo Lin School of Medicine), Singapore, with major contributions from the Buck Institute for Research on Aging (California, USA) and Texas A&M University (USA). * Corresponding author: Brian K. Kennedy.
- Journal: npj Aging (Nature Portfolio / Springer Nature).
- Impact evaluation: Reported metrics cluster around a Journal Impact Factor of roughly 6.0 (2024 to 2025 figures range from about 5.3 to 6.0 across independent trackers) and a CiteScore of about 6. Note that Nature’s own metrics page currently displays a considerably higher figure that does not agree with the independent aggregators, so the ~6 value is the more defensible one. Using the requested framing: the impact score of this journal is approximately 6.0, evaluated against a typical high-end range of 0 to 60+ for top general science journals, therefore this is a Medium impact journal.
